Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc.
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
52,00 €
-1,89 %
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $80.00 price target on the stock, up previously from $60.00.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $82.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $95.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Morgan Stanley from $95.00 to $90.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Piper Sandler from $135.00 to $130.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Morgan Stanley from $90.00 to $84.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $72.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Robert W. Baird from $57.00 to $68.00. They now have an "outperform" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $84.00 to $88.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Robert W. Baird from $68.00 to $72.00. They now have an "outperform" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Stifel Nicolaus from $124.00 to $127.00. They now have a "buy" rating on the stock.
Ratings data for RARE provided by MarketBeat
Neueste Beiträge
AI_BullishBabe in Shell plc diskutieren